GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Evidence for a role of the GHS-R1a receptors in ghrelin inhibition of gastric acid secretion in the rat.
Sibilia. V V; Muccioli. G G; Deghenghi. R R; Pagani. F F; De Luca. V V; Rapetti. D D; Locatelli. V V; Netti. C C
Key Findings
- Ghrelin’s inhibition of gastric acid secretion in rats is mediated mainly by the GHS‑R1a receptor.
- The antagonist D‑Lys(3)‑GHRP‑6 blocks ghrelin’s effect on stomach acid, confirming the receptor’s role.
- CST‑8, but not CST‑14, acts as a GHS‑R1a antagonist and can counteract ghrelin‑induced acid suppression.
Practical Outcomes
- For biohackers, this research suggests that compounds targeting GHS‑R1a (like D‑Lys(3)‑GHRP‑6) could influence stomach acid levels, but it does not provide direct dosing guidance or clear performance benefits. The findings are mainly mechanistic and may inform future experiments on gut health or ghrelin modulation rather than immediate protocol changes.
Summary
The study shows that ghrelin reduces stomach acid production by acting on the GHS‑R1a receptor, and that a synthetic blocker called D‑Lys(3)‑GHRP‑6 can stop this effect. It also finds that a short version of the neuropeptide cortistatin (CST‑8) can block ghrelin’s action, while the longer form (CST‑14) does not.
Abstract
Ghrelin, the endogenous ligand of the GH secretagogue receptor (GHS-R) has been previously shown to inhibit gastric acid secretion in pylorus-ligated rats. Two isoforms of GHS-R have been identified: GHS-R(1a) and GHS-R(1b). The present study aimed: (i) to characterise the type of GHS-R involved in the central gastric inhibitory activity of ghrelin by using des-octanoyl ghrelin, and synthetic GHS-R(1a) agonist (EP1572) and antagonist (D-Lys(3)-GHRP-6) and (ii) to investigate the relationship between ghrelin and cortistatin (CST) in the control of gastric acid secretion by using the natural neuropeptide CST-14 and the synthetic octapeptide CST-8. The specific interactions of all the compounds with GHS-R(1a) were determined by comparing their ability to displace labelled ghrelin or somatostatin from its receptors on rat hypothalamic membranes or on rat cardiomyocyte, respectively. Intracerebroventricular administration of 0.01 and 1 nmol/rat des-octanoyl ghrelin did not affect gastric acid secretion in pylorus-ligated rats, whereas EP1572 either i.c.v. (0.01-1 nmol/rat) or i.p. (10 and 20 nmol/kg) inhibited acid gastric secretion. Preteatment with D-Lys(3)GHRP-6 (3 nmol/rat, i.c.v.) was able to remove the inhibitory action of ghrelin (0.01 nmol/rat, i.c.v.) on gastric acid volume and acid output, thus indicating that the type 1a GHS-R likely mediates the gastric inhibitory action of ghrelin. This is supported by binding data showing that D-Lys(3)GHRP-6, but not des-octanoyl ghrelin, binds to hypothalamic GHS-R. CST-14 (1 nmol/rat, i.c.v.) did not affect either basal or ghrelin inhibition of gastric acid secretion. CST-8 (1 nmol/rat, i.c.v.) was able to counteract the gastric ghrelin response. The observation that CST-14 binds both GHR-S and somatostatin receptors, whereas CST-8 specifically displaces only ghrelin binding, indicates that CST-8 behaves as a GHS-R(1a) antagonist.
Study Information
pubmed
2006
2006-02-01T00:00:00.000Z
10.1111/j.1365-2826.2005.01391.x
33
59